scholarly journals Skeletal Related Events in Prostate Cancer: Important Therapeutic Considerations

10.5772/25560 ◽  
2011 ◽  
Author(s):  
Miguel Alvarez ◽  
Jesus Ma Fernandez Gomez ◽  
Antonio Jalon ◽  
Veronica Bulnes ◽  
Erasmo Miguelez ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Skeletal Related Events ◽  
Therapeutic Considerations

PO-1178: Identifying skeletal-related events for prostate cancer in routinely collected hospital data.

2020 ◽  
Vol 152 ◽  
pp. S620
Author(s):  
M. Parry ◽  
T. Cowling ◽  
A. Sujenthiran ◽  
J. Nossiter ◽  
B. Berry ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Hospital Data ◽  
Skeletal Related Events

scholarly journals Metastatic Prostate Cancer and Skeletal Related Events, a Cost of Illness Study

2014 ◽  
Vol 17 (7) ◽  
pp. A626
Author(s):  
J.W. Geenen ◽  
R. Heine ter ◽  
G.W. Frederix ◽  
A. Hövels ◽  
M. Vulpen, van ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cost Of Illness ◽  
Metastatic Prostate Cancer ◽  
Illness Study ◽  
Skeletal Related Events ◽  
Cost Of Illness Study

scholarly journals Skeletal-Related Events among Breast and Prostate Cancer Patients: Towards New Treatment Initiation in Malaysia's Hospital Setting

2013 ◽  
Vol 14 (5) ◽  
pp. 3357-3362 ◽  
Author(s):  
Sharifa Wan Puteh Ezat ◽  
Syed Mohamed Aljunid Syed Junid ◽  
Noraziani Khamis ◽  
Zafar Ahmed ◽  
Saperi Sulong ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Treatment Initiation ◽  
Hospital Setting ◽  
Skeletal Related Events ◽  
Breast And Prostate Cancer ◽  
New Treatment

scholarly journals Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2034
Author(s):  
Soraia Lobo-Martins ◽  
Arlindo R. Ferreira ◽  
André Mansinho ◽  
Sandra Casimiro ◽  
Kim Leitzel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Unmet Need ◽  
Bone Alkaline Phosphatase ◽  
Multicenter Clinical Trial ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Therapeutic Landscape ◽  
Skeletal Related Events ◽  
The Impact

The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has substantially evolved over the last decade. Nonetheless, a better understanding of bone-targeted agents (BTAs) action in mCRPC remains an unmet need. Theuse of BTAs aims to reduce the incidence of skeletal-related events (SREs) in patients with mCRPC. Less frequent BTA schedules are currently being studied to minimize adverse events. In this study, the impact of metastatic compartment (bone and extraskeletal metastases (BESM) vs. bone-only metastases (BOM)) on bone biomarker kinetics, time to first on-study SRE, and symptomatic skeletal events (SSEs) is evaluated. This is a retrospective analysis of the prospective, randomized, multicenter clinical trial of denosumab vs. zoledronic acid in patients with mCRPC and bone metastases. A total of 1901 patients were included, 1559 (82.0%) with BOM and 342 with BESM (18.0%). Bone metastases burden was balanced between groups. Baseline levels and normalization rates of corrected urinary N-terminal telopeptide and bone alkaline phosphatase did not differ between groups. However, BESM patients had a higher risk of SREs (adjusted HR 1.21; 95% CI 1.01–1.46; p = 0.043) and SSEs (adjusted HR 1.30; 95% CI 1.06–1.61; p = 0.014). This difference was more pronounced in the first 12 months of BTA treatment.In mCRPC, strategies of BTA schedule de-escalation may take into account presence of extraskeletal metastases.

scholarly journals Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide

2017 ◽  
Vol 13 (11) ◽  
pp. 720-727 ◽  
Author(s):  
Joseph J. Shatzel ◽  
Molly M. Daughety ◽  
Sven R. Olson ◽  
Tomasz M. Beer ◽  
Thomas G. DeLoughery
Keyword(s):  
Prostate Cancer ◽  
Heart Valves ◽  
Progression Free Survival ◽  
Castration Resistant Prostate Cancer ◽  
Androgen Receptor Antagonist ◽  
Body Of Knowledge ◽  
Castration Resistant ◽  
Concurrent Use ◽  
Management Paradigms ◽  
Skeletal Related Events

Enzalutamide, a novel, oral androgen receptor antagonist used for the treatment of metastatic, castration-resistant prostate cancer, has been shown to improve overall and progression-free survival, prolong time to initiation of chemotherapy, reduce skeletal-related events, and carry a favorable adverse effect profile. Metastatic prostate cancer is a disease of older men, a population with an increased incidence of medical comorbidities warranting anticoagulation. Prostate cancer itself, along with some of its therapies, is also prothrombotic. Enzalutamide interacts with several anticoagulants through various mechanisms, making their concurrent use clinically challenging. As such, complex decisions about anticoagulation in these patients are frequently encountered by treating physicians. In this review, we describe the potential interactions between enzalutamide and various anticoagulants, and suggest management paradigms based on the current body of knowledge for patients with atrial fibrillation, venous thromboembolism, and mechanical heart valves.

scholarly journals Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice

2012 ◽  
Vol 6 (6) ◽  
pp. 465 ◽  
Author(s):  
Alan So ◽  
Joseph Chin ◽  
Neil Fleshner ◽  
Fred Saad
Keyword(s):  
Prostate Cancer ◽  
Targeted Therapy ◽  
Zoledronic Acid ◽  
Bone Metastases ◽  
Therapy Monitoring ◽  
Standard Of Care ◽  
Negative Consequences ◽  
Risk Of Death ◽  
Increased Risk ◽  
Skeletal Related Events

Skeletal-related events (SREs) are a common complication of bone metastases, and have serious negative consequences for patients with castrate-resistant prostate cancer (CRPC). SREs can lead to severe pain, increased risk of death, increased health care costs and reduced quality of life. Until recently, zoledronic acid has been the sole standard of care for the prevention of SREs in men with CRPC with bone metastases. Denosumab, a receptor activator of nuclear factor kappa-B ligand (RANK-L) inhibitor, has been recently approved for use in Canada for this indication, thus presenting another option for these patients. Denosumab was shown to be superior to zoledronic acid in delaying the time to first or subsequent SREs in CRPC patients with bone metastases. This review discusses current and previous trials examining agents designed to prevent SREs in men with CRPC and bone metastases. It also discusses the practical aspects of administering a bone-targeted therapy, including choosing a bone-targeted therapy, monitoring at the onset and during therapy, switching from one therapy to another, and assessing potential complications.

Sign in / Sign up

Export Citation Format

Share Document